Clinical trials: Blood Insulin
Diabetes
Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose
In this study, QS-M needle-free injector and needle-insulin pen were used as a drug carrier to control blood glucose in type 2 diabetic patients（T2DM）.The efficacy and safety of QS-M needle-free injector and needle-insulin pen…
- Trial name
- NCT03243903
- Testing
- QS-M insulin-free injector, conventional insulin pen
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Beijing QS Medical Technology Co., Ltd.
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
Diabetes Mellitus
A Two Part Study of Peroral Insulin in Type 2 Diabetes
Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine.
- Trial name
- ORA2 (NCT00990444)
- Testing
- Insulin in Dextran Matrix
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Bows Pharmaceuticals AG
Diabetes
A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals
The study objectives are described below: 1. Obtain matched serum, plasma [(K2 EDTA, Sodium Heparin (NaH), Lithium Heparin (LiH)] and urine specimens collected from a minimum of 50 healthy subjects.
- Trial name
- NCT02614170
- Testing
- Prospective Blood Draw
- Where
- United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Fujirebio Diagnostics, Inc.
Blood Glucose, Blood Insulin
Postprandial Response to Fruit Juice
The goal of this clinical trial is to determine postprandial responses to fruit juices.
- Trial name
- NCT07103083
- Testing
- Beverage 1, Beverage 2, Beverage 3
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Ocean Spray Cranberries, Inc.
Diabetes, Diabetes Mellitus, Type 2
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in China. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of insulin detemir or NPH-insulin given once daily at bedtime as add-on to oral anti-diabetic…
- Trial name
- NCT00383877
- Testing
- insulin detemir, insulin NPH
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Novo Nordisk A/S
Postprandial Hyperglycemia
Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™
This study was a partly controlled laboratory-based study comparing the glycemic and insulinemic indices of 3 test meals containing soft drink alone or with SUGARDOWN™ (Galactomannan) in overweight adults.
- Trial name
- NCT03374501
- Testing
- Sugardown™, Soft drink
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boston Therapeutics
Healthy
To Test the Effect of Selected Fibres and Flours in Flat Bread on Post-Prandial Blood Glucose and Insulin Responses in Healthy Indian Population
Double-blind, randomized, controlled, cross-over design with 3 test products and one control product. To evaluate the effect of 4 different flour compositions (guar gum 2% and 4%, chickpea flour 15% and barley flour 2% and 5%) of…
- Trial name
- NCT02814357
- Testing
- Control (market standard), wheat flour, chickpea flour
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Prediabetes, Normoglycemic
Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile, Gastric Emptying and GLP-1 Release in Normoglycemic and Prediabetic Subjects
Aim of the study is to investigate the postprandial response on blood glucose, insulin, C-peptide, incretin response and gastric emptying after intake of collagen hydrolysate compared to placebo in normoglycemic and in…
- Trial name
- NCT06789263
- Testing
- Collagen hydrolyzed peptides
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Diabetes Mellitus, Pre-Diabetes
Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels
The purpose of the study is to evaluate the efficacy and safety of PreCrea® on subjects with higher than normal blood sugar levels.
- Conditions
- Diabetes Mellitus, Pre-Diabetes, Hyperglycemia, Metabolic Syndrome
- Trial name
- Precrea (NCT02189005)
- Testing
- Study dietary supplement (PreCrea 600 mg capsules)
- Where
- 6 sites in India
- Volunteers
- 210 people
- Sponsor
- Joe Fenn
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
Diabetes
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
- Trial name
- NCT04973111
- Testing
- CT-868 as SC Injection, Active Comparator as SC Injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Type 2 Diabetes Mellitus
Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)
Multicenter, Open-label, Randomized Trial to Compare the Effectiveness of Structured Education and Safety of FreeStyle Libre or Self-Monitoring of Blood Glucose (SMBG) in patients with type 2 Diabetes Mellitus using Multiple…
- Trial name
- NCT04926623
- Testing
- FreeStyle Libre 24 weeks, SMBG (22 weeks) and blind CGM (2 weeks)
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hepatitis C, Chronic
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus.
- Trial name
- NCT01200225
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.
- Trial name
- NCT00411892
- Testing
- pioglitazone, inhaled human insulin
- Where
- 110 sites in United States
- Volunteers
- 196 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2…
- Trial name
- COMBINE 4 (NCT06269107)
- Testing
- IcoSema, Insulin glargine
- Where
- 118 sites in United States, China and 8 more
- Volunteers
- 485 people
- Sponsor
- Novo Nordisk A/S
Hepatitis C, Chronic, Insulin Resistance
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT00493805
- Testing
- Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
This trial is conducted in Asia. This single arm trial aims to evaluate the blood glucose control with twice daily biphasic insulin aspart 30 in combination with metformin in Chinese subjects with type 2 diabetes inadequately…
- Trial name
- NCT00669864
- Testing
- biphasic insulin aspart 30, metformin
- Where
- China
- Volunteers
- 293 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
This is a 2 centres, randomised, double blind, three-treatment, three-period cross-over trial in subjects with type 1 diabetes mellitus.
- Trial name
- NCT02739906
- Testing
- BioChaperone Human Insulin (HinsBet®), Insulin Lispro (Humalog®), Regular human insulin (Huminsulin® Normal)
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia